A Phase 2 Open-Label, Multicenter, Study to Evaluate the Efficacy and Safety of Rivoceranib in Subjects with Recurrent or Metastatic Adenoid Cystic Carcinoma of All Anatomic Sites of Origin
This is a Phase 2, multicenter, open-label, single-arm study of rivoceranib to evaluate its efficacy and safety in adult subjects with metastatic ACC of all anatomic sites of origin.
Primary Objective: To evaluate the efficacy of rivoceranib in subjects with recurrent or metastatic adenoid cystic adenocarcinoma (ACC) based on assessment of objective response rate (ORR). Secondary Objective: To further evaluate the efficacy in subjects with recurrent or metastatic ACC: Overall survival (OS), Disease control rate (DCR), Progression free survival (PFS) and Time to progression (TTP). To evaluate the safety of rivoceranib. Exploratory Objectives: To explore pharmacodynamics markers, to evaluate the pharmacokinetics (PK) of revoceranib. To evaluate quality of life measurements during treatment with rivoceranib.
Back to top
Please call 1-888-663-3488 for support from a Moffitt representative. New Patients and Healthcare Professionals can submit an online form by selecting the appropriate button below. Existing patients can call 1-888-663-3488. Click here for a current list of insurances accepted at Moffitt.
NEW PATIENTS To request a new patient appointment, please fill out the online form or call 1-888-663-3488.
REFERRING PHYSICIANS Providers and medical staff can refer patients by submitting our online referral form.
Moffit now offers Virtual Visits for patients. If you are eligible for a virtual appointment, our scheduling team will discuss this option further with you.